CLINICAL_TRIALS ClinicalTrials.gov record update

A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab (6mg) in Patients With Neovascular Age-related Macular Degeneration (nAMD)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04632056
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:28.686700+00:00
Published At: 2023-11-14T00:00:00+00:00
Record Updated At: 2023-11-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Neovascular Age-related Macular Degeneration"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-11-14"
protocolSection.identificationModule.nctId: "NCT04632056"
protocolSection.identificationModule.officialTitle: "A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab (6mg) in Patients With Neovascular Age-related Macular Degeneration (nAMD)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.